Yousef Zakharia, MD, clinical associate professor of internal medicine at the University of Iowa, Holden Comprehensive Cancer Center, discusses the results of a phase 2 trial (NCT02891161) investigating concurrent durvalumab (Imfinzi) and radiation therapy followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder.
This study enrolled 26 patients and the investigators had efficacy data for 24 patients. This regimen was deemed safe for use in patients and the safety has been presented prior to the efficacy. There were no major dose-limiting toxicities with this combination, according to Zakharia.
In the 24 evaluable patients, there was a disease control rate of 72% at the end of 1 year. After the completion of adjuvant daratumumab, there were 10 complete response, 3 partial responses, 1 patient with stable disease, and 6 patients with progressive disease. Zakharia says the progression-free survival rate was about 70%. The 1-year overall survival probability was 83.8% and the 2-year probability was 76.8%. The median overall survival had not been reached.
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More